Skip to main content

RETRACTION article

Front. Oncol., 24 June 2021
Sec. Cancer Molecular Targets and Therapeutics

Retraction: Corrigendum: Tan IIA Combined With DDP Inhibits Esophageal Squamous Cell Carcinoma via Down-Regulating the NF-kB/COX-2/VEGF Pathway

Frontiers Editorial Office* Frontiers Editorial Office*
  • Frontiers Media SA, Lausanne, Switzerland

A Retraction of the Correction Article
Corrigendum: Combination of Tanshinone IIA and Cisplatin Inhibits Esophageal Cancer by Downregulating NF-κB/COX-2/VEGF Pathway

by Liao, X., Gao, Y., Liu, J., Tao, L., Wang, D., Xie, D. and Mo, S. (2021). Front. Oncol. 11:670798. doi: 10.3389/fonc.2021.670798

The Journal retract the 6 April 2021 article cited above for the following reasons:

Following publication, concerns were raised regarding the integrity of the images in the published figures. The authors failed to provide a satisfactory explanation during the investigation, which was conducted in accordance with Frontiers’ policies.

This retraction was approved by the Chief Editors of Frontiers in Oncology and the Chief Executive Editor of Frontiers. The authors did not agree to this retraction.

Citation: Frontiers Editorial Office (2021) Retraction: Corrigendum: Tan IIA Combined With DDP Inhibits Esophageal Squamous Cell Carcinoma via Down-Regulating the NF-kB/COX-2/VEGF Pathway. Front. Oncol. 11:721663. doi: 10.3389/fonc.2021.721663

Received: 07 June 2021; Accepted: 07 June 2021;
Published: 24 June 2021.

Edited and reviewed by:

Giuseppe Giaccone, Cornell University, United States

Copyright © 2021 Frontiers Editorial Office. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Frontiers Editorial Office, ZWRpdG9yaWFsLm9mZmljZUBmcm9udGllcnNpbi5vcmc=

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.